HighTide Therapeutics, Inc., stock code: 2511, issued a voluntary announcement on January 19, 2024 announcing plans to expand its business to Hebei Province, China. The Group currently has offices and R&D centers in Shenzhen, Shanghai, Nanchang and Hong Kong and expects to expand its business in Hebei Province to attract top talent in North China, strengthen industry and regulatory registration resources, and enhance raw material supply capabilities. The move will also facilitate strategic cooperation in the development, production and commercialization of the Group's core products in China. Currently, the Group is conducting feasibility studies on the proposed business expansion and communicating with local governments and stakeholders. The Company will issue further announcements as required at the appropriate time. Shareholders and potential investors should act with caution.

HighTide Therapeutics, Inc., stock code: 2511, issued a voluntary announcement on January 19, 2024 announcing plans to expand its business to Hebei Province, China. The Group currently has offices and R&D centers in Shenzhen, Shanghai, Nanchang and Hong Kong and expects to expand its business in Hebei Province to attract top talent in North China, strengthen industry and regulatory registration resources, and enhance raw material supply capabilities. The move will also facilitate strategic cooperation in the development, production and commercialization of the Group's core products in China. Currently, the Group is conducting feasibility studies on the proposed business expansion and communicating with local governments and stakeholders. The Company will issue further announcements as required at the appropriate time. Shareholders and potential investors should act with caution.